Loading
Latest filing published 26 Sept 2023 for Reata Pharmaceuticals INC. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Colin John Meyer is a declared insider of Reata Pharmaceuticals Inc (senior executive), with filings sourced from SEC (Form 4). Between 14 June 2021 and 26 September 2023, the trades on record add up to 10 filings.
Every open-market trade on record is a sale: 3 sales worth €730k. Other entries cover 4 share grants. So far in 2023, the count stands at no purchases and 3 sales.
The latest filing, published on 26 September 2023, reports a transaction in Reata Pharmaceuticals Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations